Department of Anesthesiology and Reanimation Clinic, Malatya Training and Research Hospital, Malatya, Turkey.
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5885-5892. doi: 10.26355/eurrev_202306_32828.
In this study, our goal was to assess the neutrophil/lymphocyte, platelet/lymphocyte ratios, urea/albumin, lactate, C-reactive protein/albumin procalcitonin/albumin, dehydrogenase/albumin, and protein/albumin rates in 368 critical COVID-19 cases following the entrance to the intensive care unit (ICU) to investigate the effects of biomarkers on prognosis and mortality.
The Ethics Committee approved this study carried out in our hospital's intensive care units between March 2020 and April 2022. 368 patients, 220 (59.8%) male, and 148 (40.2%) female, diagnosed with COVID-19 and aged between 18 and 99 years were included in this research.
The average age of non-survivors was statistically considerably higher than survivors (p<0.05). There was no numerical significance in terms of gender concerning mortality (p>0.05). The duration of ICU stay was statistically considerably prolonged in survivors than in those who did not survive (p<0.05). The leukocytes, neutrophils, urea, creatinine, ferritin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatine kinase (CK), C-reactive protein (CRP), procalcitonin (PCT), and pro-brain natriuretic peptide (pro-BNP) levels were numerically considerably higher in the non-survivors (p<0.05). The platelet, lymphocyte, protein, and albumin levels statistically considerably declined in non-survivors in comparison with survivors (p<0.05).
Acute renal failure (ARF) increased mortality by 31.815-fold, ferritin by 0.998-fold, pro-BNP by 1-fold, procalcitonin by 574.353-fold, neutrophil/lymphocyte by 1.119-fold, CRP/albumin by 2.141-fold, and protein/albumin by 0.003-fold. It was found that the number of days in the ICU increased mortality by 1.098-fold, creatinine by 0.325-fold, CK by 1.007-fold, urea/albumin by 1.079-fold, and LDH/albumin by 1.008-fold.
本研究旨在评估 368 例重症 COVID-19 患者入重症监护病房（ICU）后中性粒细胞/淋巴细胞、血小板/淋巴细胞、尿素/白蛋白、乳酸、C 反应蛋白/白蛋白、降钙素原/白蛋白、脱氢酶/白蛋白和蛋白/白蛋白比值，以探讨生物标志物对预后和死亡率的影响。
本研究得到我院 ICU 伦理委员会批准，于 2020 年 3 月至 2022 年 4 月进行。共纳入 368 例 COVID-19 患者，其中男 220 例（59.8%），女 148 例（40.2%），年龄 18~99 岁。
非幸存者的平均年龄明显高于幸存者（p<0.05）。在死亡率方面，性别无显著差异（p>0.05）。幸存者 ICU 住院时间明显长于非幸存者（p<0.05）。非幸存者白细胞、中性粒细胞、尿素、肌酐、铁蛋白、天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、乳酸脱氢酶（LDH）、肌酸激酶（CK）、C 反应蛋白（CRP）、降钙素原（PCT）和脑钠肽前体（pro-BNP）水平明显高于幸存者（p<0.05）。非幸存者血小板、淋巴细胞、蛋白和白蛋白水平明显低于幸存者（p<0.05）。
急性肾衰竭（ARF）使死亡率增加 31.815 倍，铁蛋白增加 0.998 倍，pro-BNP 增加 1 倍，降钙素原增加 574.353 倍，中性粒细胞/淋巴细胞增加 1.119 倍，CRP/白蛋白增加 2.141 倍，蛋白/白蛋白减少 0.003 倍。ICU 住院天数增加使死亡率增加 1.098 倍，肌酐增加 0.325 倍，CK 增加 1.007 倍，尿素/白蛋白增加 1.079 倍，LDH/白蛋白增加 1.008 倍。
